Skip to main content

anti-tgf-beta monoclonal antibody sar-439459

Generic: Anti-TGF-beta Monoclonal Antibody SAR-439459

anti-tgf-beta monoclonal antibody sar-439459: 2 clinical trials tracked.

anti-tgf-beta monoclonal antibody sar-439459 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-tgf-beta monoclonal antibody sar-439459, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Osteogenesis Imperfecta
Clinical Trial Registry Records (2)

A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta

NCT05231668Registry updated 2025-09-11·Phase 1·SNY
Terminated

Primary endpoint: Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)

InterventionalRandomizedtriple16 targetStarted 2022-08Completion 2024-1113 sites · Australia, Canada, France, United StatesSanofi

Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol

NCT04643002Registry updated 2026-06-16·Phase 1/Phase 2·SNY
Recruiting

Primary endpoint: Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab

InterventionalRandomizedopen258 targetStarted 2021-01Completion 2028-0426 sites · Australia, France, Germany, Greece…Sanofi